Physician profile
Joseph A Boscia
NPI 1669437257
$701,106.37
in general payments reported to CMS, 2019-2025
66 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $88K · 2021: $32K · 2022: $139K · 2023: $173K · 2024: $141K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $311K · Travel and Lodging: $55K · Food and Beverage: $15K · Consulting Fee: $9,100 · Gift: $57.80 · Education: $36.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $310,760.00 |
| Travel and Lodging | $55,264.50 |
| Food and Beverage | $15,240.48 |
| Consulting Fee | $9,100.00 |
| Gift | $57.80 |
| Education | $36.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $617,509.94 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Mallinckrodt Hospital Products INC. | $63,163.27 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $3,974.25 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,935.28 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $1,644.89 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Electromed, INC. | $1,330.62 | 2019-2025 | Smartvest |
| Genzyme Corporation | $1,127.27 | 2019-2025 | |
| United Therapeutics Corporation | $1,029.09 | 2019-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $1,011.16 | 2019-2025 | Dupixent |
| Philips North America LLC | $640.16 | 2019-2024 | (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $562.80 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Gilead Sciences, INC. | $499.37 | 2019-2024 | Veklury |
| Amgen INC. | $493.02 | 2022-2025 | Tezspire, Tavneos |
| Mylan Specialty L.P. | $476.06 | 2019-2023 | Yupelri |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $468.20 | 2019-2025 | Winrevair, Keytruda |
| Verona Pharma, INC. | $435.14 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $331.55 | 2019-2021 | |
| Insmed, INC. | $330.86 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $328.18 | 2020-2023 | Xarelto |
| Axsome Therapeutics, INC. | $233.80 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $230.35 | 2019-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $159.24 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $121.53 | 2022-2025 | Purified Cortrophin Gel |
| Shionogi INC | $117.19 | 2022 | |
| Ethicon INC. | $112.83 | 2024 | Monarch Platform |
| Genentech USA, INC. | $99.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $95.53 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $90.43 | 2020-2021 | |
| Inogen, INC. | $90.42 | 2021-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $86.40 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Resmed Corp | $76.86 | 2019-2022 | |
| Advanced Respiratory, INC | $64.78 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $63.23 | 2019-2020 | |
| Harmony Biosciences LLC | $52.97 | 2022-2023 | Wakix |
| Jazz Pharmaceuticals INC. | $51.93 | 2022 | |
| Pfizer INC. | $50.34 | 2024 | |
| Hikma Pharmaceuticals USA | $45.71 | 2023-2024 | Ryaltris |
| Alexion Pharmaceuticals, INC. | $40.82 | 2021-2024 | Ultomiris |
| Viatris Specialty LLC | $40.59 | 2025 | Yupelri |
| Pharming Healthcare, INC. | $37.44 | 2022 | |
| Melinta Therapeutics, LLC | $34.53 | 2021 | |
| Pulmonx Corporation | $33.35 | 2020 | |
| Exact Sciences Corporation | $26.07 | 2025 | Cologuard Collection Kit |
| Body Vision Medical INC. | $22.61 | 2023 | Lungvision |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.05 | 2023 | Lifevest |
| Lilly USA, LLC | $17.46 | 2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $14.84 | 2023 | Quviviq |
| Nabriva Therapeutics, Plc | $14.64 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $14.56 | 2019 | |
| Circassia INC. | $14.25 | 2019 | |
| Inspire Medical Systems, INC. | $14.03 | 2025 | Inspire |
| Vapotherm INC | $12.82 | 2022 | |
| Shire North American Group INC | $11.77 | 2019 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$355,877.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Boscia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.